Novo Nordisk stock tumbled Monday after its experimental weight-loss drug failed to top its rival from Eli Lilly in a Phase 3 study.

Pharmac is seeking public feedback on a proposal to fund a new, additional type of insulin for people with diabetes from 1 May 2025. The new medicine (branded as Ryzodeg) is a combination of two other ...

California dedicated $100 to manufacturing insulin for diabetic residents. That effort is taking longer than Gov. Gavin ...

Type 1 Diabetes Market Rising Prevalence and Technological Advancements Drive Market Growth AUSTIN, TX, UNITED STATES, February 28, 202 ...

Novo Nordisk has followed suit with reductions of up to 75% from the start of next year. The discount affects several of its older long- and short-acting insulin brands in both vial and pre-filled ...

AS Heart Month reminds us of the critical need to protect our cardiovascular and metabolic health, Novo Nordisk Philippines and the Philippine College of Endocrinology, Diabetes and Metabolism (PCEDM) ...

The drugmaker Novo Nordisk can meet current and future demand in the U.S., the Food and Drug Administration said. But patients may still see some supply disruptions as the medications move from ...

The U.S. Food and Drug Administration declared that the shortage of Novo Nordisk’s NOVO.B0.51%increase; green up pointing triangle weight-loss medications Wegovy and Ozempic has been resolved ...

European stocks rose for a ninth straight week, boosted by shares of chemicals companies and Novo Nordisk A/S gains. Traders are also looking ahead to German elections on Sunday. The Stoxx Europe ...

Novo Nordisk (NYSE: NVO) stock ran up 3.5% through 10:05 a.m. ET Friday morning on some good news for it (and for Eli Lilly) that's also probably bad news for Hims & Hers Health (NYSE: HIMS).